Peer-influenced content. Sources you trust. No registration required. This is HCN.

Features:
CME JOBS OUTBREAKS PEER-TO-PEER QUIZZES & QUESTIONS MEDTECH

BloodPhase 3 Trial of Gilteritinib plus Azacitidine vs. Azacitidine for Newly Diagnosed FLT3(mut+) AML Ineligible for Intensive Chemotherapy

The CRc rate was higher with GIL + AZA than with AZA in FLT3mut+ AML patients who were not suitable for intensive chemotherapy. In addition, OS did not differ significantly between GIL + AZA and AZA in FLT3mut+ AML patients who were not suitable for intensive chemotherapy.

Was this Essential useful?

More Essentials From

ACP Internist
Annals of Internal Medicine
British Medical Journal
Cancer Therapy Advisor
Cleveland Clinic Journal of Medicine
Clinical Advisor
Consultant360
Dana-Farber Cancer Institute
Epoch Health
Healthgrades for Professionals
MDLinx
Neurology Advisor
Oncology Learning Network
Oncology News Central (ONC)
Psych Congress Network
Psychiatrist.com
The New England Journal of Medicine
The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form